COVID-19 Research

The COVID-19 pandemic: a potential treatment / vaccination against SARS-CoV-2

InterK’s therapeutic candidate IK15800 specifically inhibits the activity of kinases known to facilitate SARS-CoV viral entry and replication within cells. In addition, kinase activity responsible for the severity of lung inflammation is inhibited by IK15800.

Furthermore, IK15800-enhanced IFNγ production by immune cells may have therapeutic benefit given that SARS-CoV viral replication and expression of the coronavirus binding-enzyme on host cells, ACE2, is inhibited by IFNγ.

Finally, IK15800-enhanced production of IL-15 and expression of the IL-15 receptor, IL-15Rα (CD215) by immune cells, raises the possibility that IK15800 may be useful as an adjuvant in vaccination against SARS-CoV-2.

InterK is actively seeking partnerships with national/international health organisations and biopharmaceutical companies in order to work toward potential solutions to the COVID-19 pandemic. 

Preclinical development of peptide based therapeutic candidates in Sydney Australia

Share this page